Forest Ray

Articles Authored by Forest Ray
Invitae Bets on Oncology Portfolio to Drive Growth as it Streamlines, Integrates Test Services
Premium
In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings.
Unique inflammation-associated gene expression signatures in adult and pediatric AML patients may speed risk stratification and treatment decisions.
Gene Expression Score IDs Breast Cancer Patients Responsive to Histone Deacetylase 6 Inhibitor
Premium
The gene activity signature could serve as a predictive biomarker for HDAC6 inhibitor response among metastatic breast cancer patients.
Myriad Genetics Generates More Data on its PRS's Ability to Identify Who Will Develop Breast Cancer
Premium
In a validation study presented at SABCS, Myriad evaluated how well breast cancer risk assessments made with a clinco-genomic risk score aligned with observed incidence.
Diaceutics, PMC Identify Ways Lung Cancer Patients Are Losing Out on Precision Oncology Therapies
Premium
Gaps in the biomarker testing process and knowledge deficiencies are keeping nearly two-thirds of lung cancer patients from receiving precision oncology treatments, research shows.

Researchers showed that methylation patterns on cell-free DNA in the eye can differentiate retinoblastomas into more or less aggressive subtypes.
Veto of California Bill Mandating Payor Coverage of Biomarker Tests Sparks Stakeholder Debate
Premium
Nonspecific language in California Gov. Gavin Newsom's veto of a bill to mandate insurance coverage of evidence-based biomarker tests caused confusion among the bill's proponents.
The funding is allocated to the California Initiative to Advance Precision Medicine for research related to depression and underrepresented populations.
A2 Biotherapeutics Enrolling Patients in Clinical Study of New CAR-T Therapy Using Tempus NGS Panel
Premium
The Tmod CAR-T platform uses tumor- and non-tumor-specific elements to spare normal cells while killing tumor cells without sacrificing cytotoxic potency.
Protein-Based Liquid Biopsy Panel Assesses Tumor Microenvironment, Shows Prognostic Potential
Premium
A panel of 13 circulating proteins related to the tumor microenvironment may provide prognostic clues to prostate cancer progression.